XML 105 R7.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Operating Activities        
Net income $ 1,671 $ 1,528 $ 4,985 $ 4,727
Adjustments to reconcile net income to cash provided by operating activities:        
Depreciation 602 580 1,792 1,729
Deferred and other income taxes     77 59
Other operating activities, net     (52) (121)
Changes in current assets and liabilities:        
Accounts receivable, net     37 (38)
Materials and supplies     (32) (29)
Other current assets     (92) (73)
Accounts payable and other current liabilities     (82) (381)
Income and other taxes     51 111
Cash provided by operating activities     6,684 5,984
Investing Activities        
Capital investments     (2,530) (2,582)
Other investing activities, net     104 (68)
Cash used in investing activities     (2,426) (2,650)
Financing Activities        
Dividends paid     (2,403) (2,380)
Debt repaid     (2,220) (2,179)
Share repurchase programs (Note 16)     (831) (705)
Debt issued (Note 14)     800 1,599
Other financing activities, net     279 125
Cash used in financing activities     (4,375) (3,540)
Net change in cash, cash equivalents, and restricted cash     (117) (206)
Cash, cash equivalents, and restricted cash at beginning of year     1,074 987
Cash, cash equivalents, and restricted cash at end of period 957 781 957 781
Non-cash investing and financing activities:        
Capital investments accrued but not yet paid     153 187
Cash paid during the period for:        
Income taxes, net of refunds     (1,219) (1,155)
Interest, net of amounts capitalized     (1,074) (1,113)
Reconciliation of cash, cash equivalents, and restricted cash to the Condensed Consolidated Statement of Financial Position:        
Cash and cash equivalents 947 750 947 750
Restricted cash equivalents in other current assets 2 22 2 22
Restricted cash equivalents in other assets 8 9 8 9
Total cash, cash equivalents, and restricted cash equivalents per above $ 957 $ 781 $ 957 $ 781